Saposin C and other sphingolipid activator proteins

Gaucher Disease

Volumn , Issue , 2006, Pages 67-84

  Hoops, Silvia Locatelli ^a   Kolter, Thomas ^a   Sandhoff, Konrad ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 81455135648     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420005509     Document Type: Chapter

References (105)

1. Fürst, W. and Sandhoff, K., Activator proteins and topology of lysosomal sphingolipid catabolism, Biochim. Biophys. Acta. 1126, 1, 1992.
2. Möbius, W. et al., Recycling compartments and the internal vesicles of multivesicular bodies harbor most of the cholesterol found in the endocytic pathway, Traffic. 4, 222, 2003.
3. Burkhardt, J.K. et al., Accumulation of sphingolipids in SAP-precursor (prosaposin)- deficient fibroblasts occurs as intralysosomal membrane structures and can be completely reversed by treatment with human SAP-precursor, Eur. J. Cell Biol. 73, 10, 1997.
4. Wilkening, G. et al., Degradation of membrane-bound ganglioside GM1. Stimulation by bis(monoacylglycero)phosphate and the activator proteins SAP-B and GM2-AP, J. Biol. Chem. 275, 35814, 2000.
5. Werth, N. et al., Degradation of membrane-bound ganglioside GM2 by beta-hexosaminidase A. Stimulation by GM2 activator protein and lysosomal lipids, J. Biol. Chem.,276, 12685, 2001.
6. Berent, S.L. and Radin, N.S., Mechanism of activation of glucocerebrosidase by cobeta- glucosidase (glucosidase activator protein), Biochim. Biophys. Acta. 664, 572, 1981.
7. Sarmientos, F., Schwarzmann, G., and Sandhoff, K., Specificity of human glucosylceramide beta-glucosidase towards synthetic glucosylsphingolipids inserted into liposomes. Kinetic studies in a detergent-free assay system, Eur. J. Biochem. 160, 527, 1986.
8. Salvioli, R. et al., Further studies on the reconstitution of glucosylceramidase activity by Sap C and anionic phospholipids, FEBS Lett. 472, 17, 2000.
9. Sandhoff K. et al., Sphingolipid activator proteins, in The Metabolic and Molecular Bases of Inherited Disease, Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D., Eds., McGraw-Hill, New York, 2004, chapter 134.
10. Mehl, E. and Jatzkewitz, H., Eine Cerebrosidsulfatase aus Schweineniere, Hoppe Seylers Z. Physiol. Chem. 339, 260, 1964.
11. Ho, M.W. and O’Brien, J.S., Gaucher’s disease: deficiency of ‘acid’-glucosidase and reconstitution of enzyme activity in vitro, Proc. Natl. Acad. Sci. U.S.A. 68, 2810, 1971.
12. Prence, E. et al., Further studies on the activation of glucocerebrosidase by a heatstable factor from Gaucher spleen, Arch. Biochem. Biophys. 236, 98, 1985.
13. Fabbro, D. and Grabowski, G.A., Human acid beta-glucosidase. Use of inhibitory and activating monoclonal antibodies to investigate the enzyme’s catalytic mechanism and saposin A and C binding sites, J. Biol. Chem. 266, 15021, 1991.
14. Sandhoff, K., The biochemistry of sphingolipid storage diseases, Angew. Chem. Int. Ed. Engl. 16, 273, 1977.
15. Conzelmann, E. and Sandhoff, K., AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2, Proc. Natl. Acad. Sci. U.S.A. 75, 3979, 1978.
16. Conzelmann, E. and Sandhoff, K., Purification and characterization of an activator protein for the degradation of glycolipids GM2 and GA2 by hexosaminidase A, Hoppe Seylers Z. Physiol. Chem. 360, 1837, 1979.
17. Fujibayashi, S. and Wenger, D.A., Synthesis and processing of sphingolipid activator protein-2 (SAP-2) in cultured human fibroblasts, J. Biol. Chem. 261, 15339, 1986.
18. Fujibayashi, S. and Wenger, D.A., Biosynthesis of the sulfatide/GM1 activator protein (SAP-1) in control and mutant cultured skin fibroblasts, Biochim. Biophys. Acta. 875, 554, 1986.
19. Fürst, W., Machleidt, W., and Sandhoff, K., The precursor of sulfatide activator protein is processed to three different proteins, Biol. Chem. Hoppe Seyler. 369, 317, 1988.
20. Furst, W. et al., The complete amino-acid sequences of human ganglioside GM2 activator protein and cerebroside sulfate activator protein, Eur. J. Biochem. 192, 709, 1990.
21. Morimoto, S. et al., Saposin A: second cerebrosidase activator protein, Proc. Natl. Acad. Sci. U.S.A. 86, 3389, 1989.
22. O’Brien, J.S. et al., Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus, Science. 241, 1098, 1988.
23. Nakano, T., Sandhoff, K., Stumper, J., Christomanou, H., and Suzuki, K., Structure of full-length cDNA coding for sulfatide activator, a Co-beta-glucosidase and two other homologous proteins: two alternate forms of the sulfatide activator, J. Biochem. (Tokyo), 105, 152 (1989).
24. Christomanou, H., Aignesberger, A., and Linke, R.P., Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant, Biol. Chem. Hoppe Seyler. 367, 879, 1986.
25. Schnabel, D., Schröder, M., and Sandhoff, K., Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease, FEBS Lett. 284, 57, 1991.
26. Vaccaro, A.M. et al., Structural analysis of saposin C and B. Complete localization of disulfide bridges, J. Biol. Chem. 270, 9953, 1995.
27. Kishimoto, Y., Hiraiwa, M., and O’Brien, J.S., Saposins: structure, function, distribution, and molecular genetics, J. Lipid Res. 33, 1255, 1992.
28. Munford, R.S., Sheppard, P.O., and O’Hara, P.J., Saposin-like proteins (SAPLIP) carry out diverse functions on a common backbone structure, J. Lipid Res. 36, 1653, 1995.
29. Liepinsh, E. et al., Saposin fold revealed by the NMR structure of NK-lysin, Nat. Struct. Biol. 4, 793, 1997.
30. Hecht, O. et al., Solution structure of the pore-forming protein of Entamoeba histolytica, J. Biol. Chem. 279, 17834, 2004.
31. Leippe, M. et al., Ancient weapons: the three-dimensional structure of amoebapore A, Trends Parasitol. 21, 5, 2005.
32. Nakano, T. et al., Structure of full-length cDNA coding for sulfatide activator, a Cobeta- glucosidase and two other homologous proteins: two alternate forms of the sulfatide activator, J. Biochem. (Tokyo). 105, 152, 1989.
33. Hiraiwa, M. et al., Isolation, characterization, and proteolysis of human prosaposin, the precursor of saposins (sphingolipid activator proteins), Arch. Biochem. Biophys., 304, 110, 1993.
34. Lefrancois, S. et al., The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin, Embo J. 22, 6430, 2003.
35. Lefrancois, S., Canuel, M., Zeng, J., and Morales, C.R., Inactivation of sortilin (a novel lysosomal sorting receptor) by dominant negative competition and RNA interference, Biol. Proced. Online. 7, 17, 2005.
36. Vielhaber, G., Hurwitz, R., and Sandhoff, K., Biosynthesis, processing, and targeting of sphingolipid activator protein (SAP) precursor in cultured human fibroblasts. Mannose 6-phosphate receptor-independent endocytosis of SAP precursor, J. Biol. Chem. 271, 32438, 1996.
37. Berent, B.L. and Radin, N.S., beta-Glucosidase activator protein from bovine spleen (“coglucosidase”), Arch. Biochem. Biophys. 208, 248, 1981.
38. Kleinschmidt, T., Christomanou, H., and Braunitzer, G., Complete amino-acid sequence and carbohydrate content of the naturally occurring glucosylceramide activator protein (A1 activator) absent from a new human Gaucher disease variant, Biol. Chem. Hoppe Seyler. 368, 1571, 1987.
39. Sano, A. and Radin, N.S., The carbohydrate moiety of the activator protein for glucosylceramide beta-glucosidase, Biochem. Biophys. Res. Commun. 154, 1197, 1988.
40. Kleinschmidt, T., Christomanou, H., and Braunitzer, G., Complete amino-acid sequence and carbohydrate content of the naturally occurring glucosylceramide activator protein (A1 activator) absent from a new human Gaucher disease variant, Biol. Chem. Hoppe Seyler. 368, 1571, 1987.
41. Vaccaro, A.M. et al., Structural analysis of saposin C and B. Complete localization of disulfide bridges, J. Biol. Chem. 270, 9953, 1995.
42. Sun, Y., Qi, X., and Grabowski, G.A., Saposin C is required for normal resistance of acid beta-glucosidase to proteolytic degradation, J. Biol. Chem. 278, 31918, 2003.
43. Klein, A. et al., Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo, Biochem. Biophys. Res. Commun. 200, 1440, 1994.
44. Zschoche, A. et al., Hydrolysis of lactosylceramide by human galactosylceramidase and GM1-beta-galactosidase in a detergent-free system and its stimulation by sphingolipid Eur J activator proteins, sap-B and sap-C. Activator proteins stimulate lactosylceramide hydrolysis, Eur. J. Biochem. 222, 83, 1994.
45. Wenger, D.A., Sattler, M., and Roth, S., A protein activator of galactosylceramide beta-galactosidase, Biochim. Biophys. Acta. 712, 639, 1982.
46. Poulos, A. et al., Studies on the activation of sphingomyelinase activity in Niemann-Pick type A, B, and C fibroblasts: enzymological differentiation of types A and B, Pediatr. Res. 18, 1088, 1984.
47. de Alba, E., Weiler, S., and Tjandra, N., Solution structure of human saposin C: pHdependent interaction with phospholipid vesicles, Biochemistry. 42, 14729, 2003.
48. Hawkins, C.A., Alba, E., and Tjandra, N., Solution structure of human saposin C in a detergent environment, J. Mol. Biol. 346, 1381, 2005.
49. Ho, M.W. and Rigby, M., Glucocerebrosidase: stoichiometry of association between effector and catalytic proteins, Biochim. Biophys. Acta. 397, 267, 1975.
50. Ho, M.W. and Light, N.D., Glucocerebrosidase: reconstitution from macromolecular components depends on acidic phospholipids, Biochem. J. 136, 821, 1973.
51. Vaccaro, A.M. et al., pH-dependent conformational properties of saposins and their interactions with phospholipid membranes, J. Biol. Chem. 270, 30576, 1995.
52. Weiler, S. et al., Identification of the binding and activating sites of the sphingolipid activator protein, saposin C, with glucocerebrosidase, Protein Sci. 4, 756, 1995.
53. You, H.X., Qi, X., and Yu, L., Direct AFM observation of saposin C-induced membrane domains in lipid bilayers: from simple to complex lipid mixtures, Chem. Phys. Lipids. 132, 15, 2004.
54. Wilkening, G., Linke, T., and Sandhoff, K., Lysosomal degradation on vesicular membrane surfaces. Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators, J. Biol. Chem. 273, 30271, 1998.
55. Chu, Z., Witte, D.P., and Qi, X., Saposin C-LBPA interaction in late-endosomes/lysosomes, Exp. Cell Res. 303, 300, 2005.
56. Qi, X. and Chu, Z., Fusogenic domain and lysines in saposin C, Arch. Biochem. Biophys. 424, 210, 2004.
57. Salvioli, R. et al., Glucosylceramidase mass and subcellular localization are modulated by cholesterol in Niemann-Pick disease type C, J. Biol. Chem. 279, 17674, 2004.
58. Spiegel, R. et al., A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: first report of saposin A deficiency in humans, Mol. Genet. Metab., 84, 160, 2005.
59. Matsuda, J. et al., A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse, Hum. Mol. Genet. 10, 1191, 2001.
60. Morimoto, S. et al., Saposin A: second cerebrosidase activator protein, Proc. Natl. Acad. Sci. U.S.A. 86, 3389, 1989.
61. Morimoto, S. et al., Interaction of saposins, acidic lipids, and glucosylceramidase, J. Biol. Chem. 265, 1933, 1990.
62. Kretz, K.A. et al., Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect, Proc. Natl. Acad. Sci. U.S A. 87, 2541, 1990.
63. Li, S.C. et al., Activator protein required for the enzymatic hydrolysis of cerebroside sulfate. Deficiency in urine of patients affected with cerebroside sulfatase activator deficiency and identity with activators for the enzymatic hydrolysis of GM1 ganglioside and globotriaosylceramide, J. Biol. Chem. 260, 1867, 1985.
64. Conzelmann, E., Lee-Vaupel, M., and Sandhoff, K., The physiological roles of activator proteins for lysosomal glycolipid degradation, in Lipid storage disorders, Salvayre, R., Douste-Blazy, L., and Gatt, S., Eds., Plenum Publishing, New York, 1988, p. 323.
65. Ahn, V.E. et al., Crystal structure of saposin B reveals a dimeric shell for lipid binding, Proc. Natl. Acad. Sci. U.S.A. 100, 38, 2003.
66. Matsuda, J. et al., Mutation in saposin D domain of sphingolipid activator protein gene causes urinary system defects and cerebellar Purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in mouse, Hum. Mol. Genet., 13, 2709, 2004.
67. Sano, A. et al., Sphingolipid hydrolase activator proteins and their precursors, Biochem. Biophys. Res. Commun., 165, 1191, 1989.
68. Kondoh, K. et al., Isolation and characterization of prosaposin from human milk, Biochem. Biophys. Res. Commun. 181, 286, 1991.
69. Hineno, T. et al., Secretion of sphingolipid hydrolase activator precursor, prosaposin, Biochem. Biophys. Res. Commun. 176, 668, 1991.
70. O’Brien, J.S. et al., Identification of the neurotrophic factor sequence of prosaposin, Faseb J. 9, 681, 1995.
71. Tsuboi, K., Hiraiwa, M., and O’Brien, J.S., Prosaposin prevents programmed cell death of rat cerebellar granule neurons in culture, Brain Res. Dev. Brain Res. 110, 249, 1998.
72. Kotani, Y. et al., Prosaposin facilitates sciatic nerve regeneration in vivo, J. Neurochem., 66, 2019, 1996.
73. Kotani, Y. et al., A hydrophilic peptide comprising 18 amino acid residues of the prosaposin sequence has neurotrophic activity in vitro and in vivo, J. Neurochem., 66, 2197, 1996.
74. Lapchak, P.A. et al., Prosaptide exacerbates ischemia-induced behavioral deficits in vivo; an effect that does not involve mitogen-activated protein kinase activation, Neuroscience. 101, 811, 2000.
75. Hiraiwa, M. et al., Cell death prevention, mitogen-activated protein kinase stimulation, and increased sulfatide concentrations in Schwann cells and oligodendrocytes by prosaposin and prosaptides, Proc. Natl. Acad. Sci. U.S.A. 94, 4778, 1997.
76. Rende, M. et al., Prosaposin is immunolocalized to muscle and prosaptides promote myoblast fusion and attenuate loss of muscle mass after nerve injury, Muscle Nerve. 24, 799, 2001.
77. Morales, C.R., and Badran, H., Prosaposin ablation inactivates the MAPK and Akt signaling pathways and interferes with the development of the prostate gland, Asian J. Androl. 5, 57, 2003.
78. Amann, R.P., Seidel, G.E., Jr., and Brink, Z.A., Exposure of thawed frozen bull sperm to a synthetic peptide before artificial insemination increases fertility, J. Androl. 20, 42, 1999.
79. Schuette, C.G. et al., Sphingolipid activator proteins: proteins with complex functions in lipid degradation and skin biogenesis, Glycobiology, 11, 81R, 2001.
80. Holleran, W.M. et al., Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function, J. Clin. Invest. 91, 1656, 1993.
81. Doering, T., Proia, R.L., and Sandhoff, K., Accumulation of protein-bound epidermal glucosylceramides in beta-glucocerebrosidase deficient type 2 Gaucher mice, FEBS Lett., 447, 167 (1999).
82. Doering, T., Holleran, W.M., Potratz, A., Vielhaber, G., Elias, P.M., Suzuki, K., and Sandhoff, K., Sphingolipid activator proteins are required for epidermal permeability barrier formation, J. Biol. Chem. 274, 11038, 1999.
83. Gallala, H., Macheleidt, O., Doering, T., Schreiner, V., and Sandhoff, K., Nitric oxide regulates synthesis of gene products involved in keratinocyte differentiation and ceramide metabolism, Eur. J. Cell Biol. 83, 667, 2004.
84. Doering, T., Brade, H., and Sandhoff, K., Sphingolipid metabolism during epidermal barrier development in mice, J. Lipid Res. 43, 1727, 2002.
85. Sidransky, E., Sherer, D.M., and Ginns, E.I., Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene, Pediatr. Res. 32, 494, 1992.
86. Fujita, N. et al., Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids, Hum. Mol. Genet. 5, 711, 1996.
87. Kronenberg, M., Presenting fats with SAPs, Nat. Immunol. 5, 126, 2004.
88. Winau, F. et al., Saposin C is required for lipid presentation by human CD1b, Nat. Immunol., 5, 169, 2004.
89. Kang, S.J. and Cresswell, P., Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells, Nat. Immunol. 5, 175, 2004.
90. Zhou, D. et al., Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins, Science. 303, 523, 2004.
91. Bradova, V. et al., Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease, Hum. Genet. 92, 143, 1993.
92. Schnabel, D. et al., Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene, J. Biol. Chem. 267, 3312, 1992.
93. Elleder, M. et al., Prosaposin deficiency - a rarely diagnosed, rapidly progressing, neonatal neurovisceral lipid storage disease. Report of a further patient, Neuropediatrics. 36, 171, 2005.
94. Hulkova, H. et al., A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation, Hum. Mol. Genet. 10, 927, 2001.
95. Christomanou, H. et al., Activator protein deficient Gaucher’s disease. A second patient with the newly identified lipid storage disorder, Klin Wochenschr. 67, 999, 1989.
96. Rafi, M.A. et al., Mutational analysis in a patient with a variant form of Gaucher disease caused by SAP-2 deficiency, Somat. Cell. Mol. Genet. 19, 1, 1993.
97. Pampols, T., Pineda, M., Giros, M.L., Ferrer, I., Cusi, V., Chabas, A., Sanmarti, F.X., Vanier, M.T., and Christomanou, H., Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant, Acta Neuropathol. (Berl.). 97, 91, 1999.
98. Sandhoff, K. and Kolter, T. Topology of glycosphingolipid degradation, Trends Cell. Biol. 6, 98, 1996.
99. Kolter, T. and Sandhoff, K., Recent advances in the biochemistry of sphingolipidoses, Brain Pathol. 8, 79, 1998.
100. Henseler, M. et al., Analysis of a splice site mutation in the SAP precursor gene of a patient with metachromatic leukodystrophy, Am. J. Hum. Genet. 58, 65, 1996.
101. Rafi, M.A. et al., Detection of a point mutation in sphingolipid activator protein-1 mRNA in patients with a variant form of metachromatic leukodystrophy, Biochem. Biophys. Res. Commun. 166, 1017, 1990.
102. Holtschmidt, H. et al., Sulfatide activator protein. Alternative splicing that generates three mRNAs and a newly found mutation responsible for a clinical disease, J. Biol. Chem., 266, 7556, 1991.
103. Zhang, X-L. et al., Insertion in the mRNA of a metachromatic leukodystrophy patient with sphingolipid activator protein-1 deficiency, Proc. Natl. Acad. Sci. U.S.A. 87, 1426, 1990.
104. Zhang, X.L. et al., The mechanism for a 33-nucleotide insertion in messenger RNA causing sphingolipid activator protein (SAP-1)-deficient metachromatic leukodystrophy, Hum. Genet., 87, 211, 1991.
105. Wrobe, D. et al., A non-glycosylated and functionally deficient mutant (N215H) of the sphingolipid activator protein B (SAP-B) in a novel case of metachromatic leukodystrophy (MLD), J. Inherit. Metab. Dis., 23, 63, 2000.